Skip to main content
. Author manuscript; available in PMC: 2024 Aug 1.
Published in final edited form as: Br J Haematol. 2022 Oct 18;202(4):749–759. doi: 10.1111/bjh.18519

Fig 2. Sankey diagram of treatment patterns (from 1L up to 5L).

Fig 2.

Treatment patterns of patients from 1L up to 5L (left to right) among 240 patients with relapsed/refractory mantle cell lymphoma who received BTKi between July 2012 to July 2018. The proportions (%) shown are based on total number of patients (N) receiving the preceding line of treatment (except for 1L which is based on 240 patients). 1L, first-line; 2L, second-line; 3L, third-line; 4L, fourth-line; 5L, fifth-line; BR, bendamustine + rituximab; BTKi, Bruton tyrosine kinase inhibitor; MCL, mantle cell lymphoma; R-BAC, rituximab + bendamustine + cytarabine *Others included anti-metabolite, radioimmunotherapy, radiotherapy, or unknown